Abstract
Objective: Recently, we reported that stable-phase schizophrenia is characterized by two interrelated symptom dimensions: PHEMN (psychotic, hostility, excitation, mannerism and negative symptoms); and DAPS (depressive, anxiety and physio-somatic symptoms) and that Major Neuro-Cognitive psychosis (MNP) is the full-blown phenotype of schizophrenia (largely overlapping with deficit schizophrenia). Herein we examined the effects of immune activation in association with tryptophan catabolite (TRYCAT) patterning and memory disorders on PHEMN/DAPS dimensions and MNP.
Methods: Serum levels of macrophage inflammatory protein-1 (MIP-1), soluble interleukin (IL)-1 receptor antagonist (sIL-1RA), IL-10, eotaxin, IgA/IgM responses to TRYCATs, and Consortium to Establish a Registry for Alzheimer’s disease (CERAD) tests were assessed in 40 controls and 80 schizophrenia patients.
Results: Schizophrenia and MNP were predicted by significantly increased levels of IL-10, eotaxin and TRYCATs. A large part of variance in both PHEMN/DAPS symptom dimensions (42.8%) was explained by cytokine levels and TRYCATs combined. The MIP+sIL-1RA+IL-10 composite score and eotaxin explained each around on the basis of 19% of the variance in symptom dimensions, and approximately 18% of memory deficits. Moreover, MIP+sIL-1RA+IL-10 was significantly associated with elevations in picolinic acid, xanthurenic acid and 3-OH-kynurenine. Partial Least Squares path modeling shows that highly significant effects of MIP+sIL-1RA+IL-10 on symptomatology are mediated by the effects of noxious TRYCATs on memory deficits.
Conclusion: Current findings indicate that in schizophrenia, immune activation may underpin activation of indoleamine-2,3-dioxygenase and kynurenine monooxygenase, while impairments in episodic and semantic memory may be caused by the neurotoxic effects of TRYCATs and eotaxin. The combined effects of immune activation, eotaxin and memory defects determine to a large extent, PHEMN/DAPS symptoms and the MNP phenotype. These findings indicate that schizophrenia phenomenology is largely mediated by multiple neuro-immune pathways and that immune activation, increased production of eotaxin and neurotoxic TRYCATs (picolinic acid, xanthurenic acid and 3-HOkynurenine) are new drug targets in schizophrenia and MNP.
Keywords: Deficit schizophrenia, inflammation, cytokines, immune, oxidative stress, kynurenine.
Graphical Abstract
[1]
Kanchanatawan B, Thika S, Sirivichayakul S. In Schizophrenia, depression, anxiety, and physiosomatic symptoms are strongly related to psychotic symptoms and excitation, impairments in episodic memory, and increased production of neurotoxic tryptophan catabolites: A multivariate and machine learning study. Neurotox Res 2018; 33(3): 641-55.
[2]
Crow TJ. The two-syndrome concept: Origins and current status. Schizophr Bull 1985; 11(3): 471-86.
[3]
Emsley RA, Oosthuizen PP, Joubert AF, Roberts MC, Stein DJ. Depressive and anxiety symptoms in patients with Schizophrenia and schizophreniform disorder. J Clin Psychiatry 1999; 60: 747-51.
[4]
Kirschner M, Aleman A, Kaiser S. Secondary negative symptoms - A review of mechanisms, assessment and treatment. Schizophr Res 2016; 0920-9964: 30224-30229
[5]
CERAD. CERAD - an overview: The consortium to establish a registry for alzheimer’s disease; 1986. http://cerad.mc.duke.edu/
[6]
Kanchanatawan B, Hemrungrojn S, Thika S, et al. Changes in tryptophan catabolite (TRYCAT) pathway patterning are associated with mild impairments in declarative memory in Schizophrenia and deficits in semantic and episodic memory coupled with increased false-memory creation in deficit Schizophrenia. Mol Neurobiol 2018; 55(6): 5184-201.
[7]
Kanchanatawan B, Sriswasdi S, Thika S, et al. Towards a new classification of stable phase Schizophrenia into major and simple neuro-cognitive psychosis: Results of unsupervised machine learning analysis. J Eval Clin Pract 2018.
[http://dx.doi.org/10.1111/jep.12945]
[http://dx.doi.org/10.1111/jep.12945]
[8]
Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The schedule for the deficit syndrome: an instrument for research in Schizophrenia. Psychiatry Res 1989; 30: 119-23.
[9]
Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, et al. Deficit, but not nondeficit, Schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite (trycat) pathway with highly specific increases in IGA responses directed to picolinic, xanthurenic, and quinolinic acid. Mol Neurobiol 2018; 55(2): 1524-36.
[10]
Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, et al. Deficit Schizophrenia is characterized by defects in igm-mediated responses to tryptophan catabolites (TRYCATs): A paradigm shift towards defects in natural self-regulatory immune responses coupled with mucosa-derived trycat pathway activation. Mol Neurobiol 2018; 55(3): 2214-26.
[11]
Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 702-21.
[12]
Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in Schizophrenia: Comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89(5): 346-51.
[13]
Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in Schizophrenia: Comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89(5): 346-51.
[14]
Maes M, Delange J, Ranjan R, et al. Acute phase proteins in Schizophrenia, mania and major depression: Modulation by psychotropic drugs. Psychiatry Res 1997; 66(1): 1-11.
[15]
Noto C, Ota VK, Gouvea ES, et al. Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis. Int J Neuropsychopharmacol 2014; 18(4): pyu042.
[16]
Noto C, Maes M, Ota VK, et al. High predictive value of immune-inflammatory biomarkers for Schizophrenia diagnosis and association with treatment resistance. World J Biol Psychiatry 2015; 27: 1-8.
[17]
Noto C, Ota VK, Santoro ML, et al. Depression, cytokine, and cytokine by treatment interactions modulate gene expression in antipsychotic naïve first episode psychosis. Mol Neurobiol 2016; 53(8): 5701-9.
[18]
Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012; 36(2): 764-85.
[19]
Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M. Eotaxin, an endogenous cognitive deteriorating chemokine (ecdc), is a major contributor to cognitive decline in normal people and to executive, memory, and sustained attention deficits, formal thought disorders, and psychopathology in Schizophrenia patients. Neurotox Res 2018.
[http://dx.doi.org/10.1007/s12640-018-9937-8]
[http://dx.doi.org/10.1007/s12640-018-9937-8]
[20]
Kittirathanapaiboon P, Khamwongpin M. The validity of the mini international neuropsychiatric interview (MINI) Thai version suanprung hospital. Department of Mental Health 2005.
[21]
Andreasen NC. The scale for the assessment of negative symptoms (SANS): Conceptual and theoretical foundations. Br J Psychiatry Suppl 1989; 7: 49-58.
[22]
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for Schizophrenia. Schizophr Bull 1987; 13: 261-76.
[26]
Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG. A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 2002; 52: 501-9.
[27]
Roomruangwong C, Kanchanatawan B, Sirivichayakul S, et al. IgM-mediated autoimmune responses to oxidative specific epitopes, but not nitrosylated adducts, are significantly decreased in pregnancy: Association with bacterial translocation, perinatal and lifetime major depression and the tryptophan catabolite (TRYCAT) pathway. Metab Brain Dis 2017; 32(5): 1571-83.
[28]
Duleu S, Mangas A, Sevin F, Veyret B, Bessede A, Geffard M. Circulating antibodies to IDO/THO pathway metabolites in alzheimer’s disease. Int J Alzheimers Dis 2010; 15: 2010.
[29]
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Methodol 1995; 57: 289-300.
[30]
Ringle CM, da Silva D, Bido D. Structural equation modeling with the Smart PLS Braz J Mark - BJM Revista Brasileira de Marketing - ReMark Edição Especial 2014; 13: 2
[31]
Maes M, Song C, Yirmiya R. Targeting IL-1 in depression. Expert Opin Ther Targets 2012; 16(11): 1097-2.
[32]
Sherry B, Tekamp-Olson P, Gallegos C, et al. Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta. J Exp Med 1988; 168(6): 2251-9.
[33]
Ren M, Guo Q, Guo L, et al. Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J 2010; 29(23): 3952-66.
[34]
Ying S, Robinson DS, Meng Q, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997; 27(12): 3507-16.
[35]
Adar T, Shteingart S, Ben Ya’acov A, Bar-Gil Shitrit A, Goldin E. From airway inflammation to inflammatory bowel disease: Eotaxin-1, a key regulator of intestinal inflammation. Clin Immunol 2014; 153(1): 199-208.
[36]
Mochizuki M, Bartels J, Mallet AI, Christophers E, Schröder JM. IL-4 induces eotaxin: A possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol 1998; 160(1): 60-8.
[37]
Pope SM, Brandt EB, Mishra A, et al. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 2001; 108(4): 594-601.
[38]
Teixeira AL, Reis HJ, Nicolato R, et al. Increased serum levels of CCL11/eotaxin in Schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(3): 710-4.
[39]
Pedrini M, Massuda R, de Lucena D, et al. Differences in eotaxin serum levels patients with recent onset and in chronic stable Schizophrenia: A clue for understanding accelerating aging profile. Schizophr Res 2014; 152(2-3): 528-9.
[40]
Frydecka D. KK M, Lubeiro A, et al. Profiling inflammatory signatures of Schizophrenia: A cross-sectional and meta-analysis study. Brain Behav Immun 2018; 0889-1591(18): 30173-9
[41]
Hong S, Lee EE, Martin AS, et al. Abnormalities in chemokine levels in schizophrenia and their clinical correlates. Schizophr Res 2017; 181: 63-9.
[42]
Maes M, Carvalho AF. The compensatory immune-regulatory reflex system (cirs) in depression and bipolar disorder. Mol Neurobiol 2018; 2
[http://dx.doi.org/10.1007/s12035-018-1016-x]
[http://dx.doi.org/10.1007/s12035-018-1016-x]
[43]
Morris G, Carvalho AF, Anderson G, Galecki P, Maes M. The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be associated with the pathophysiology of neuro-immune disorders. Curr Pharm Des 2016; 22(8): 963-77.
[44]
Morris G, Berk M, Carvalho A, et al. The role of the microbial metabolites including tryptophan catabolites and short chain fatty acids in the pathophysiology of immune-inflammatory and neuroimmune disease. Mol Neurobiol 2017; 54(6): 4432-51.
[45]
Erickson MA, Morofuji Y, Owen JB, Banks WA. Rapid transport of CCL11 across the blood-brain barrier: Regional variation and importance of blood cells. J Pharmacol Exp Ther 2014; 349(3): 497-507.
[46]
Wainwright DA, Xin J, Mesnard NA, Politis CM, Sanders VM, Jones KJ. Effects of facial nerve axotomy on Th2- and Th1-associated chemokine expression in the facial motor nucleus of wild-type and presymptomatic mSOD1 mice. J Neuroimmunol 2009; 216(1-2): 66-75.
[47]
Adzemovic MZ, Öckinger J, Zeitelhofer M, et al. Expression of Ccl11 associates with immune response modulation and protection against neuroinflammation in rats. PLoS One 2012; 7(7): e39794.
[48]
Lalli MA, Bettcher BM, Arcila ML, et al. Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer’s disease. Mol Psychiatry 2015; 20(11): 1294-300.
[49]
Schwieler L, Larsson MK, Skogh E, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci 2015; 40(2): 126-33.
[50]
Connor TJ, Starr N, O’Sullivan JB, Harkin A. Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma? Neurosci Lett 2008; 441(1): 29-34.
[51]
Maes M, Anderson G, Kubera M, Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets 2014; 18(5): 495-512.
[52]
Asevedo E, Rizzo LB, Gadelha A, et al. Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiol Behav 2014; 129: 194-8.
[53]
Tan Y, Li Y, Tan S, et al. Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment-resistant schizophrenia. Schizophr Res 2015; 169(1-3): 16-21.
[54]
Monteiro S, Ferreira FM, Pinto V, et al. Absence of IFNγ promotes hippocampal plasticity and enhances cognitive performance. Transl Psychiatry 2016; 6: e707.
[55]
Narasimhalu K, Lee J, Leong YL, et al. Inflammatory markers and their association with post stroke cognitive decline. Int J Stroke 2015; 10(4): 513-8.
[56]
Marciniak E, Faivre E, Dutar P, et al. The Chemokine MIP-1α/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. Sci Rep 2015; 5: 15862.
[57]
Passos GF, Figueiredo CP, Prediger RD, et al. Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. Am J Pathol 2009; 175(4): 1586-97.
[58]
Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011; 477(7362): 90-4.
[59]
Harvey PD, Koren D, Reihenberg A, Bowie CR. Negative symptoms and cognitive deficits: What is the nature of their relationship? Schizophr Bull 2006; 32: 250-8.
[60]
Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 1998; 13: 21-6.
[61]
Corlett PR, Honey GD, Fletcher PC. From prediction error to psychosis: Ketamine as a pharmacological model of delusions. J Psychopharmacol 2007; 21(3): 238-52.
[62]
Myhre SR. False memories in depression: Vulnerability factor or symptom? Thesis, North Dakota State University of Agriculture and Applied Science. Fargo, North Dakota, 2015
[63]
Frith CD, Blakemore S, Wolpert DM. Explaining the symptoms of schizophrenia: Abnormalities in the awareness of action. Brain Res Brain Res Rev 2000; 31(2-3): 357-63.
[64]
Orellana G, Slachevsky A. Executive functioning in schizophrenia. Front Psychiatry 2013; 4: 35.
[65]
Galuppi A, Turola MC, Nanni MG, Mazzoni P, Grassi L. Schizophrenia and quality of life: How important are symptoms and functioning? Int J Ment Health Syst 2010; 4: 31.
[66]
Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousoño M. Quality of life in schizophrenic patients. Dialogues Clin Neurosci 2007; 9(2): 215-26.
[67]
Serafini G, Pompili M, Haghighat R, et al. Stigmatization of schizophrenia as perceived by nurses, medical doctors, medical students and patients. J Psychiatr Ment Health Nurs 2011; 18(7): 576-85.
[68]
Sartorius N, Chiu H, Heok KE, et al. Name change for schizophrenia. Schizophr Bull 2014; 40: 255-8.
[69]
Maes M, Song C, Yirmiya R. Targeting IL-1 in depression. Expert Opin Ther Targets 2012; 16(11): 1097-112.
[70]
Opitz CA, Wick W, Steinman L, Platten M. Tryptophan degradation in autoimmune diseases. Cell Mol Life Sci 2007; 64(19-20): 2542-63.
[72]
Ushio A, Arakaki R, Yamada A, et al. Crucial roles of macrophages in the pathogenesis of autoimmune disease. World J Immunol 2017; 7(1): 1-8.
[73]
Roomruangwong C, Noto C, Kanchanatawan B, et al. The role of aberrations in the immune-inflammatory reflex system (IRS) and the compensatory immune-regulatory reflex system (cirs) in different phenotypes of schizophrenia: The IRS-CIRS theory of schizophrenia. Preprints 2018; 2018090289
[http://dx.doi.org/10.20944/ preprints201809.0289.v1]
[http://dx.doi.org/10.20944/ preprints201809.0289.v1]
[74]
Noto N, Maes M, Odebrecht VS, Kiyomi OV, et al. Activation of the immune-inflammatory response system and the compensatory immune-regulatory reflex system in antipsychotic naive first episode psychosisPreprints 2018; 090314 (doi: 1020944/preprints 2018090314v1)
[75]
Maes M, Kanchanatawan B, Sirivichayakul S, Carvalho AF. In schizophrenia, low natural igm antibody titers to oxidative specific epitopes and higher igm responses to nitrated and nitrosylated proteins strongly predict negative symptoms, neurocognitive impairments and the deficit syndrome. Preprints 2018; 100083
[http://dx.doi.org/10.20944/preprints201810.0083.v2]
[http://dx.doi.org/10.20944/preprints201810.0083.v2]
[76]
Maes M, Kanchanatawan B, Sirivichayakul S, Carvalho AF. In schizophrenia, increased plasma IgM/IgA responses to gut commensal bacteria are associated with negative symptoms, neurocognitive impairments and the deficit phenotype. Preprints 2018; 100414
[http://dx.doi.org/10.20944/preprints201810.0414.v1]
[http://dx.doi.org/10.20944/preprints201810.0414.v1]
Related Journals
Current Drug Safety
Current Neuropharmacology
Current Pharmaceutical Design
Current Neurovascular Research
Current Pharmaceutical Analysis
Central Nervous System Agents in Medicinal Chemistry
Current Vascular Pharmacology
Current Alzheimer Research
Current Molecular Pharmacology
Current Aging Science
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Frontiers in Clinical Drug Research-Dementia
Article Metrics
48
8
1
1